{'fraction_non_alphanumeric': 0.017790956263899184, 'fraction_numerical': 0.002223869532987398, 'mean_word_length': 5.852791878172589, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Crossreactivity of Bupropion Metabolite With Enzyme-Linked Immunosorbent Assays Designed to Detect Amphetamine in Urine

Background: Drug screening is rapid, inexpensive, and is often used in clinical, forensic, and workplace drug testing to gain informative results. This article seeks to determine if bupropion and/or its metabolites is resulting in false-positive amphetamine screening results in our case samples using commercially available enzyme-linked immunosorbent assay tests. Method: Fortified urine and forensic case samples were used to determine crossreactivity of bupropion and its main metabolite to four different amphetamine and methamphetamine enzyme-linked immunosorbent assay kits. Results: Two of the enzyme-linked immunosorbent assay kits used to screen for amphetamine may result in false-positive results if bupropion metabolites are present in concentrations greater than 500 ng/mL. Three case samples gave a positive screen results for amphetamine using Amphetamine ULTRA kits, yet no amphetamines were confirmed by gas chromatography-mass spectrometry and all samples were positive for bupropion and metabolites. Conclusions: Laboratory directors and clinicians should be aware of the characteristic of their chosen laboratory assay and should communicate this to physicians so that results can be interpreted accurately.